Keyphrases
South African
100%
Combination Treatment
100%
Cryptococcal Meningitis
100%
Cross-sectional Observational Study
100%
Flucytosine
100%
Access Programs
100%
Adjusted Odds Ratio
18%
In-hospital Mortality
18%
Antifungal Therapy
18%
Cerebrospinal Fluid
18%
South Africa
12%
Middle-income Countries
12%
Routine Care
12%
Laboratory Confirmation
12%
Case Fatality Rate
12%
Surveillance Site
12%
Cryptococcosis
12%
First Episode
12%
Case Report Form
12%
Enhanced Surveillance
12%
Hospital Admission
6%
Antiretroviral Therapy
6%
Clinical Practice Guidelines
6%
Communicable Diseases
6%
Illness
6%
Zulu
6%
Treatment Group
6%
HIV Status
6%
Clinical Trials
6%
Sentinel Hospital
6%
Low-income
6%
National Health
6%
Reduced Mortality
6%
Treatment Experience
6%
Laboratory Services
6%
Survivors
6%
Microscopy
6%
To Determine the Effectiveness
6%
HIV Serology
6%
Antifungal Agents
6%
Cryptococcus Neoformans
6%
Induction Treatment
6%
India Ink
6%
Non-enhancing
6%
Recurrent Episodes
6%
Non-HIV Cryptococcal Meningitis
6%
Random-effect Logistic Regression
6%
Cryptococcal Antigen Test
6%
Non-academic Hospital
6%
Induction Regimen
6%
Cryptococcus Gattii
6%
Survival Benefit
6%
Medicine and Dentistry
Observational Study
100%
Cryptococcal Meningitis
100%
Flucytosine
100%
Human Immunodeficiency Virus
18%
Hospital Mortality
18%
Cerebrospinal Fluid
18%
Antifungal Therapy
18%
Odds Ratio
18%
Case Fatality Rate
12%
Cryptococcosis
12%
Disease
6%
Cross Sectional Study
6%
Clinical Trial
6%
Health Care Cost
6%
Communicable Disease
6%
Antifungal Agent
6%
Logistic Regression Analysis
6%
Division
6%
Indian Ink
6%
Cryptococcus gattii
6%
Immunology and Microbiology
Meningitis
100%
Human Immunodeficiency Virus
75%
Hospital Mortality
75%
Cerebrospinal Fluid
75%
Case Fatality Rate
50%
Infectious Disease
25%
Serology
25%
Cryptococcus neoformans
25%
Cryptococcus gattii
25%
Pharmacology, Toxicology and Pharmaceutical Science
Observational Study
100%
Cryptococcal Meningitis
100%
Flucytosine
100%
HIV
18%
Antifungal Agent
18%
Hospital Mortality
18%
Cryptococcosis
12%
Case Fatality Rate
12%
Disease
6%
Cross-Sectional Study
6%
Clinical Trial
6%
Communicable Disease
6%
Cryptococcus neoformans
6%
Indian Ink
6%
Antifungal Therapy
6%
Cryptococcus gattii
6%